Celcuity Inc. (CELC)
| Market Cap | 3.33B +10.6% |
| Revenue (ttm) | n/a |
| Net Income | -226.48M |
| EPS | -4.32 |
| Shares Out | 48.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 885,826 |
| Open | 66.08 |
| Previous Close | 65.80 |
| Day's Range | 65.69 - 68.82 |
| 52-Week Range | 53.54 - 151.02 |
| Beta | 0.11 |
| Analysts | Strong Buy |
| Price Target | 154.72 (+127.3%) |
| Est. Earnings | Nov 11, 2026 |
About CELC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for CELC stock is "Strong Buy." The 12-month stock price target is $154.72, which is an increase of 127.30% from the latest price.
News
Celcuity announces results from PIK3CA cohort of Phase 3 VIKTORIA-1
Celcuity (CELC) announced new subgroup analyses from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 study evaluating gedatolisib in patients with HR+/HER2- locally advanced or metastatic breast ca...
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
Median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet versus 9.1 months with alpelisib + fulvestrant in patients who had no liver metastases
Celcuity announces updated results from gedatolisib trial at ESMO
Celcuity (CELC) announced updated clinical results from the Phase 1b/2 study evaluating gedatolisib in patients with metastatic castration-resistant prostate cancer, or mCRPC. These data were presente...
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
Median radiographic progression free survival (“rPFS”) was 15.7 months and the six-month rPFS rate (“rPFS6”) was 82.2% in patients who received prior abiraterone
Cantor starts Celcuity at Overweight on multi-billion sales potential
Cantor Fitzgerald initiated coverage of Celcuity (CELC) with an Overweight rating and $140 price target Celcuity is a commercial-stage oncology company that recently launched its first product, Revtor...
Celcuity initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Li Watsek initiated coverage of Celcuity (CELC) with an Overweight rating and $140 price target
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort Poster presentation of a comparative analysis of data for the gedatolisib triplet from the PIK3CA...
Celcuity appoints Gryska to Board of Directors
Celcuity (CELC) announced the appointment of David Gryska to its Board of Directors. Throughout the past 25 years, Gryska has served on the Boards of eight public biotechnology companies and…
Celcuity Appoints David Gryska To Its Board Of Directors
Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity's Board Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity's Board
Celcuity announces REVTORPYK is now commercially available in U.S.
Celcuity (CELC) announced that REVTORPYK is now commercially available in the United States for eligible patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, loc...
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or after at least one line of endocrine therapy in the metastatic ...
Celcuity initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Celcuity (CELC) with an Overweight rating and $157 price target The firm cites the long-term potential of Revtorpyk in breast cancer for the buy rating. The…
Celcuity Transcript: Citigroup’s Biopharma Back to School Summit 2026
REVTORPYK is launching for HR-positive, HER2-negative advanced breast cancer, with broad physician awareness and robust market access groundwork. Multiple phase III studies are ongoing in breast and prostate cancer, and expanded manufacturing is planned to support future growth.
Celcuity Transcript: Wells Fargo 21st Annual Healthcare Conference
REVTORPYK received approval for second-line metastatic breast cancer, with commercial launch planned this quarter and a supplemental NDA for PIK3CA mutant patients under review. Strong clinical data, flexible regimens, and a robust commercial strategy position the drug for significant market impact.
Celcuity To Participate in Upcoming Investor Conferences
MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid t...
Celcuity submits Revtorpyk sNDA to the FDA
Celcuity (CELC) announced the submission of its supplemental new drug application, or sNDA, to the FDA for Revtorpyk for the treatment of patients with hormone receptor positive, human epidermal growt...
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, ...
Celcuity price target raised to $175 from $165 at Guggenheim
Guggenheim analyst Brad Canino raised the firm’s price target on Celcuity (CELC) to $175 from $165 and keeps a Buy rating on the shares. Celcuity remains well positioned ahead of…
Celcuity reports Q2 EPS ($1.07), consensus ($1.16)
“Celcuity (CELC) made monumental progress these past few months, achieving critical clinical and regulatory milestones related to gedatolisib. With the FDA approval of REVTORPYK, positive results from...
Celcuity price target lowered to $150 from $175 at Stifel
Stifel lowered the firm’s price target on Celcuity (CELC) to $150 from $175 and keeps a Buy rating on the shares. Management reiterated confidence in its ability to begin shipping…
Celcuity price target lowered to $140 from $157 at Needham
Needham lowered the firm’s price target on Celcuity (CELC) to $140 from $157 and keeps a Buy rating on the shares after its Q2 results and company’s updates following Revtorpyk’s…
Celcuity Earnings Call Transcript: Q2 2026
FDA approved REVTORPYK for HR-positive, HER2-negative advanced breast cancer, with commercial launch set for late Q3 2026 and a $6B+ U.S. market opportunity. Q2 net loss widened due to launch investments, but cash reserves are strong following a $575M convertible note.
Celcuity Earnings release: Q2 2026
Celcuity released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Celcuity Quarterly report: Q2 2026
Celcuity has published its Q2 2026 quarterly earnings report on August 13, 2026.
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tu...